An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.

In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in ...

In a phase 1 trial, a gene-editing therapy that targets ANGPTL3 was associated with few serious adverse events and at higher ...

CorriXR Therapeutics, Inc., an oncology-focused biotherapeutics company pioneering a novel gene editing platform to overcome drug resistance in solid tumors, today announced the publication of a ...

The approach is “very exciting,” but one expert says a lot more research is needed, especially around safety, before clinical ...

A Greer couple is hosting a fundraiser to support a costly gene editing procedure for their two children, who suffer from a ...

Researchers in Australia have led a first-in-human trial for a breakthrough gene-editing therapy that halves bad cholesterol ...

Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...

The inventor of base and prime editing shares insights on medicine's efforts to make serious genetic diseases treatable or ...

Researchers report early but encouraging results on an experimental gene-editing treatment for high cholesterol.

In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...

In a highly anticipated article, FDA officials Vinay Prasad, M.D., and Martin Makary, M.D., outlined a novel regulatory ...